193 related articles for article (PubMed ID: 30419344)
1. Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway.
De Veirman K; Menu E; Maes K; De Beule N; De Smedt E; Maes A; Vlummens P; Fostier K; Kassambara A; Moreaux J; Van Ginderachter JA; De Bruyne E; Vanderkerken K; Van Valckenborgh E
Cancer Lett; 2019 Feb; 442():233-241. PubMed ID: 30419344
[TBL] [Abstract][Full Text] [Related]
2. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
De Veirman K; Van Ginderachter JA; Lub S; De Beule N; Thielemans K; Bautmans I; Oyajobi BO; De Bruyne E; Menu E; Lemaire M; Van Riet I; Vanderkerken K; Van Valckenborgh E
Oncotarget; 2015 Apr; 6(12):10532-47. PubMed ID: 25871384
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.
Wang ST; Huang SW; Kao JK; Liang SM; Chen YJ; Chen YY; Wu CY; Shieh JJ
J Dermatol Sci; 2015 May; 78(2):108-16. PubMed ID: 25766763
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
5. Exogenous H2S Inhibits Autophagy in Unilateral Ureteral Obstruction Mouse Renal Tubule Cells by Regulating the ROS-AMPK Signaling Pathway.
Chen Q; Yu S; Zhang K; Zhang Z; Li C; Gao B; Zhang W; Wang Y
Cell Physiol Biochem; 2018; 49(6):2200-2213. PubMed ID: 30257249
[TBL] [Abstract][Full Text] [Related]
6. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
7. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
8. AMPK activation induced by promethazine increases NOXA expression and Beclin-1 phosphorylation and drives autophagy-associated apoptosis in chronic myeloid leukemia.
Medeiros HCD; Colturato-Kido C; Ferraz LS; Costa CA; Moraes VWR; Paredes-Gamero EJ; Tersariol ILS; Rodrigues T
Chem Biol Interact; 2020 Jan; 315():108888. PubMed ID: 31682805
[TBL] [Abstract][Full Text] [Related]
9. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells.
Zaman S; Wang R; Gandhi V
Exp Hematol; 2015 Nov; 43(11):951-962.e3. PubMed ID: 26257207
[TBL] [Abstract][Full Text] [Related]
10. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway.
Vucicevic L; Misirkic M; Janjetovic K; Vilimanovich U; Sudar E; Isenovic E; Prica M; Harhaji-Trajkovic L; Kravic-Stevovic T; Bumbasirevic V; Trajkovic V
Autophagy; 2011 Jan; 7(1):40-50. PubMed ID: 20980833
[TBL] [Abstract][Full Text] [Related]
11. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Jaganathan S; Malek E; Vallabhapurapu S; Vallabhapurapu S; Driscoll JJ
Oncotarget; 2014 Dec; 5(23):12358-70. PubMed ID: 25481044
[TBL] [Abstract][Full Text] [Related]
13. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
15. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.
Romano A; Parrinello NL; La Cava P; Tibullo D; Giallongo C; Camiolo G; Puglisi F; Parisi M; Pirosa MC; Martino E; Conticello C; Palumbo GA; Di Raimondo F
Expert Rev Mol Diagn; 2018 Jul; 18(7):675-683. PubMed ID: 29707981
[TBL] [Abstract][Full Text] [Related]
16. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
17. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells.
Gomez-Bougie P; Bataille R; Amiot M
Eur J Immunol; 2004 Nov; 34(11):3156-64. PubMed ID: 15459900
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
Min H; Xu M; Chen ZR; Zhou JD; Huang M; Zheng K; Zou XP
Cancer Chemother Pharmacol; 2014 Jul; 74(1):167-76. PubMed ID: 24842158
[TBL] [Abstract][Full Text] [Related]
19. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
20. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Muto A; Hori M; Sasaki Y; Saitoh A; Yasuda I; Maekawa T; Uchida T; Asakura K; Nakazato T; Kaneda T; Kizaki M; Ikeda Y; Yoshida T
Mol Cancer Ther; 2007 Mar; 6(3):987-94. PubMed ID: 17363492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
